<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650880</url>
  </required_header>
  <id_info>
    <org_study_id>UW20-004</org_study_id>
    <nct_id>NCT04650880</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D on Ovulation Rate in Women With Polycystic Ovary Syndrome</brief_title>
  <official_title>A Randomized Double-blind Controlled Trial on the Effect of Vitamin D on Ovulation Rate of Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kwong Wah Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Margaret Hospital, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blind controlled trial on the effect of vitamin D supplementation&#xD;
      to assess the ovulation rate of women with polycystic ovary syndrome (PCOS) and other&#xD;
      reproductive, endocrine and metabolic outcomes after one year of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis is that vitamin D supplementation results in significant improvement in the&#xD;
      ovulation rate of women with PCOS either spontaneously or with oral ovulation induction&#xD;
      agent.&#xD;
&#xD;
      Anovulatory women with PCOS diagnosed by the Rotterdam criteria will be recruited.&#xD;
&#xD;
      Participants will be randomized to the (1) vitamin D group or (2) placebo group. Those in the&#xD;
      vitamin D group will take vitamin D 50,000 IU/ week for 4 weeks, followed by 50,000IU once&#xD;
      every 2 weeks for 52 weeks, whereas those in the placebo group will take placebo tablets with&#xD;
      the same external appearance. Those who remain anovulatory after 6 months will be treated&#xD;
      with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to&#xD;
      response) for ovulation induction.&#xD;
&#xD;
      The primary outcome is the ovulation rate and will be compared between the 2 groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovulation rate</measure>
    <time_frame>12 months</time_frame>
    <description>Serum progesterone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum 25(OH)D level</measure>
    <time_frame>12 months</time_frame>
    <description>Serum 25(OH)D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>12 months</time_frame>
    <description>Positive urine or serum hCG test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>12 months</time_frame>
    <description>Delivery of a baby after 22 completed weeks of gestational age, or with birth weight of 500 grams if the gestation age is unknown, which shows evidence of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum anti-Mullerian hormone level</measure>
    <time_frame>12 months</time_frame>
    <description>serum AMH level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in antral follicle count</measure>
    <time_frame>12 months</time_frame>
    <description>Antral follicle count measured by transvaginal/ transrectal ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androgen indices</measure>
    <time_frame>12 months</time_frame>
    <description>serum androgen and androstenedione levels, SHBG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>12 months</time_frame>
    <description>Height in cm, weight in kg, to calculate the body mass index (kg/m^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist and hip circumference</measure>
    <time_frame>12 months</time_frame>
    <description>waist and hip circumference in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of diabetes mellitus/ impaired glucose intolerance</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by fasting and 2 hour glucose (post 75g OGTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic and diastolic blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Anovulation</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D 50,000 IU/ week for 4 weeks, followed by 50,000 IU once every 2 weeks for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets with same external appearance for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Vitamin D supplementation</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets with the same external appearance</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Premenopausal&#xD;
&#xD;
          -  Aged 18-40 years&#xD;
&#xD;
          -  Irregular long menstrual cycles (&gt;35 days)&#xD;
&#xD;
          -  PCOS according to the Rotterdam criteria&#xD;
&#xD;
          -  Agree for transvaginal ultrasound&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of hormonal medication (including contraception) within 3 months prior to study&#xD;
             inclusion, except the use of a progestogen to induce withdrawal bleeding every 3&#xD;
             months&#xD;
&#xD;
          -  History of any medical condition or medications that may predispose to vitamin D&#xD;
             sensitivity, altered vitamin D metabolism and/ or hypercalcemia, including active&#xD;
             tuberculosis or current therapy for tuberculosis, sarcoidosis, history of renal/&#xD;
             ureteral stones, parathyroid disease, renal or liver failure or current use of&#xD;
             anti-convulsants&#xD;
&#xD;
          -  Use of insulin-sensitizing drugs, lipid lowering drugs or anti-hypertensive&#xD;
&#xD;
          -  Anticipated to use the above medications in the coming one year&#xD;
&#xD;
          -  Known type 2 diabetes mellitus&#xD;
&#xD;
          -  Refusal to join the study&#xD;
&#xD;
          -  Abnormal blood calcium level&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kwong Wah Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shui Fan Lai, MBBS, MRCOG</last_name>
      <phone>+852 35175183</phone>
      <email>lsf087@ha.org.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Queenie Ho Yan Wong, MBBS, MRCOG</last_name>
      <phone>+852 29903430</phone>
      <email>why442@ha.org.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital, University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Ka Yee Ko, MBBS</last_name>
      <phone>22554647</phone>
      <email>jenko@hku.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Anovulation</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>review by investigators</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

